妊娠期惊恐障碍、广泛性焦虑障碍及苯二氮䓬治疗与不良出生结局的关联
这项队列研究在2005至2009年招募2654名孕妇,评估妊娠期惊恐障碍、广泛性焦虑障碍及苯二氮䓬或5-羟色胺再摄取抑制剂治疗与不良母婴结局的关联。调整混杂后,惊恐障碍和广泛性焦虑障碍与不良结局无关,但苯二氮䓬暴露与剖宫产、低出生体重和新生儿通气支持相关,5-羟色胺再摄取抑制剂暴露与妊娠期高血压疾病、早产和轻微呼吸干预相关。
要点
- 妊娠期惊恐障碍或广泛性焦虑障碍本身未增加不良母婴结局风险。
- 苯二氮䓬暴露与剖宫产、低出生体重及新生儿通气支持风险升高相关。
- 5-羟色胺再摄取抑制剂暴露与妊娠期高血压疾病、早产及轻微呼吸干预相关。
核心结论
- 惊恐障碍和广泛性焦虑障碍不导致不良妊娠并发症。
- 妊娠期药物治疗可能轻微缩短孕周,5-羟色胺再摄取抑制剂还与妊娠期高血压疾病和剖宫产相关。
研究设计与样本
- 这项队列研究于2005年7月1日至2009年7月14日在康涅狄格州和马萨诸塞州137家产科诊所招募孕17周前女性,并在孕28±4周和产后8±4周重新评估。
- 精神科诊断依据世界精神卫生复合国际诊断访谈的答案确定,最终分析纳入2654名女性。
主要发现
- 在调整模型中,惊恐障碍和广泛性焦虑障碍均与感兴趣的母婴并发症无关。
- 母亲苯二氮䓬使用与剖宫产(OR 2.45;95%CI 1.36-4.40)、低出生体重(OR 3.41;95%CI 1.61-7.26)和新生儿通气支持(OR 2.85;95%CI 1.2-6.9)相关。
- 母亲5-羟色胺再摄取抑制剂使用与妊娠期高血压疾病(OR 2.82;95%CI 1.58-5.04)、早产(OR 1.56;95%CI 1.02-2.38)和轻微呼吸干预(OR 1.81;95%CI 1.39-2.37)相关。
- 苯二氮䓬治疗使每1000名新生儿中通气支持增加61例,孕周缩短3.6天;5-羟色胺再摄取抑制剂使孕周缩短1.8天,每1000名新生儿中额外152例需轻微呼吸干预,每1000名女性中额外53例发生妊娠期高血压疾病。
临床怎么用
- 临床应认识到惊恐障碍和广泛性焦虑障碍本身不增加不良妊娠结局风险,但需权衡妊娠期药物治疗的潜在风险。
- 对使用苯二氮䓬或5-羟色胺再摄取抑制剂的孕妇,应加强监测剖宫产、低出生体重、早产、妊娠期高血压疾病及新生儿呼吸支持需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Registry data show that maternal panic disorder, or anxiety disorders in general, increase the risk for adverse pregnancy outcomes. However, diagnoses from registries may be imprecise and may not consider potential confounding factors, such as treatment with medication and maternal substance use. OBJECTIVE: To determine whether panic disorder or generalized anxiety disorder (GAD) in pregnancy, or medications used to treat these conditions, are associated with adverse maternal or neonatal pregnancy outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study conducted between July 1, 2005, and July 14, 2009, recruited women at 137 obstetric practices in Connecticut and Massachusetts before 17 weeks of pregnancy and reassessed them at 28 (±4) weeks of pregnancy and 8 (±4) weeks postpartum. Psychiatric diagnoses were determined by answers to the World Mental Health Composite International Diagnostic Interview. Assessments also gathered information on treatment with medications and confounding factors, such as substance use, previous adverse birth outcomes, and demographic factors. EXPOSURE: Panic disorder, GAD, or use of benzodiazepines or serotonin reuptake inhibitors. MAIN OUTCOMES AND MEASURES: Among mothers: preterm birth, cesarean delivery, and hypertensive diseases of pregnancy. Among neonates: low birth weight, use of minor respiratory interventions, and use of ventilatory support. RESULTS: Of the 2654 women in the final analysis (mean [SD] age, 31.0 [5.7] years), most were non-Hispanic white (1957 [73.7%]), 98 had panic disorder, 252 had GAD, 67 were treated with a benzodiazepine, and 293 were treated with a serotonin reuptake inhibitor during pregnancy. In adjusted models, neither panic disorder nor GAD was associated with maternal or neonatal complications of interest. Most medication exposures occurred early in pregnancy. Maternal benzodiazepine use was associated with cesarean delivery (odds ratio [OR], 2.45; 95% CI, 1.36-4.40), low birth weight (OR, 3.41; 95% CI, 1.61-7.26), and use of ventilatory support for the newborn (OR, 2.85; 95% CI, 1.2-6.9). Maternal serotonin reuptake inhibitor use was associated with hypertensive diseases of pregnancy (OR, 2.82; 95% CI, 1.58-5.04), preterm birth (OR, 1.56; 95% CI, 1.02-2.38), and use of minor respiratory interventions (OR, 1.81; 95% CI, 1.39-2.37). With maternal benzodiazepine treatment, rates of ventilatory support increased by 61 of 1000 neonates and duration of gestation was shortened by 3.6 days; with maternal serotonin reuptake inhibitor use, gestation was shortened by 1.8 days, 152 of 1000 additional newborns required minor respiratory interventions, and 53 of 1000 additional women experienced hypertensive diseases of pregnancy. CONCLUSIONS AND RELEVANCE: Panic disorder and GAD do not contribute to adverse pregnancy complications. Women may require treatment with medications during pregnancy, which can shorten the duration of gestation slightly. Maternal treatment with a serotonin reuptake inhibitor is also associated with hypertensive disease of pregnancy and cesarean delivery.
引用
- Yonkers KA, Gilstad-Hayden K, Forray A, et al. Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes. JAMA Psychiatry. 2017. PMID: 28903165. doi:10.1001/jamapsychiatry.2017.2733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。